Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination

Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is crit...

Descripción completa

Detalles Bibliográficos
Autores: González-Pérez, María, Montes-Casado, María, Conde, Patricia, Cervera, Isabel, Baranda, Jana, Berges-Buxeda, Marcos J., Pérez-Olmeda, Mayte, Sanchez-Tarjuelo, Rodrigo, Utrero-Rico, Alberto, Lozano-Ojalvo, Daniel, Torre, Denis, Schwarz, Megan, Guccione, Ernesto, Cámara, Carmen, Llópez-Carratalá, M. Rosario, Gonzalez-Parra, Emilio, Portolés, María Pilar, Ortiz, Alberto, Portoles, Jose, Ochando, Jordi
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/269547
Acceso en línea:http://hdl.handle.net/10261/269547
Access Level:acceso abierto
Palabra clave:COVID-19
SARS-CoV-2 vaccine
Hemodialysis
Chronic kidney disease
Cellular response
Humoral responses
id ES_736f8a3f2b09edf5e70a3e162e597152
oai_identifier_str oai:digital.csic.es:10261/269547
network_acronym_str ES
network_name_str España
repository_id_str
spelling Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 VaccinationGonzález-Pérez, MaríaMontes-Casado, MaríaConde, PatriciaCervera, IsabelBaranda, JanaBerges-Buxeda, Marcos J.Pérez-Olmeda, MayteSanchez-Tarjuelo, RodrigoUtrero-Rico, AlbertoLozano-Ojalvo, DanielTorre, DenisSchwarz, MeganGuccione, ErnestoCámara, CarmenLlópez-Carratalá, M. RosarioGonzalez-Parra, EmilioPortolés, María PilarOrtiz, AlbertoPortoles, JoseOchando, JordiCOVID-19SARS-CoV-2 vaccineHemodialysisChronic kidney diseaseCellular responseHumoral responsesLong-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population.Funding was obtained from Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001), FEDER funds; Acción Estratégica en Salud Intramural (AESI), Instituto de Salud Carlos III, grant number AESI PI21CIII_00022 to PP and Healthstar-plus -REACT-UE Grant through Segovia Arana Research Institute Puerta de Hierro Majadahonda-IDIPHIM. JO is a member of VACCELERATE (European Corona Vaccine Trial Accelerator Platform) Network, which aims to facilitate and accelerate the design and implementation of COVID-19 phase 2 and 3 vaccine trials. JO is a member of the INsTRuCT under the MSC grant agreement Nº860003 (Innovative Training in Myeloid Regulatory Cell Therapy) Consortium, a network of European scientists from academia and industry focused on developing innovative immunotherapies.Peer reviewedFrontiers MediaInstituto de Salud Carlos IIIEuropean CommissionConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202220222022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/269547reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.3389/fimmu.2022.845882Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2695472026-05-22T06:33:51Z
dc.title.none.fl_str_mv Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
spellingShingle Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
González-Pérez, María
COVID-19
SARS-CoV-2 vaccine
Hemodialysis
Chronic kidney disease
Cellular response
Humoral responses
title_short Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_full Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_fullStr Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_full_unstemmed Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_sort Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
dc.creator.none.fl_str_mv González-Pérez, María
Montes-Casado, María
Conde, Patricia
Cervera, Isabel
Baranda, Jana
Berges-Buxeda, Marcos J.
Pérez-Olmeda, Mayte
Sanchez-Tarjuelo, Rodrigo
Utrero-Rico, Alberto
Lozano-Ojalvo, Daniel
Torre, Denis
Schwarz, Megan
Guccione, Ernesto
Cámara, Carmen
Llópez-Carratalá, M. Rosario
Gonzalez-Parra, Emilio
Portolés, María Pilar
Ortiz, Alberto
Portoles, Jose
Ochando, Jordi
author González-Pérez, María
author_facet González-Pérez, María
Montes-Casado, María
Conde, Patricia
Cervera, Isabel
Baranda, Jana
Berges-Buxeda, Marcos J.
Pérez-Olmeda, Mayte
Sanchez-Tarjuelo, Rodrigo
Utrero-Rico, Alberto
Lozano-Ojalvo, Daniel
Torre, Denis
Schwarz, Megan
Guccione, Ernesto
Cámara, Carmen
Llópez-Carratalá, M. Rosario
Gonzalez-Parra, Emilio
Portolés, María Pilar
Ortiz, Alberto
Portoles, Jose
Ochando, Jordi
author_role author
author2 Montes-Casado, María
Conde, Patricia
Cervera, Isabel
Baranda, Jana
Berges-Buxeda, Marcos J.
Pérez-Olmeda, Mayte
Sanchez-Tarjuelo, Rodrigo
Utrero-Rico, Alberto
Lozano-Ojalvo, Daniel
Torre, Denis
Schwarz, Megan
Guccione, Ernesto
Cámara, Carmen
Llópez-Carratalá, M. Rosario
Gonzalez-Parra, Emilio
Portolés, María Pilar
Ortiz, Alberto
Portoles, Jose
Ochando, Jordi
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Salud Carlos III
European Commission
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv COVID-19
SARS-CoV-2 vaccine
Hemodialysis
Chronic kidney disease
Cellular response
Humoral responses
topic COVID-19
SARS-CoV-2 vaccine
Hemodialysis
Chronic kidney disease
Cellular response
Humoral responses
description Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/269547
url http://hdl.handle.net/10261/269547
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.3389/fimmu.2022.845882
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410810021806080
score 15,812455

Similares en LA Referencia